1. Home
  2. MTVA vs CING Comparison

MTVA vs CING Comparison

Compare MTVA & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MTVA
  • CING
  • Stock Information
  • Founded
  • MTVA 2014
  • CING 2012
  • Country
  • MTVA United States
  • CING United States
  • Employees
  • MTVA N/A
  • CING N/A
  • Industry
  • MTVA
  • CING Biotechnology: Pharmaceutical Preparations
  • Sector
  • MTVA
  • CING Health Care
  • Exchange
  • MTVA NYSE
  • CING Nasdaq
  • Market Cap
  • MTVA 16.8M
  • CING 15.3M
  • IPO Year
  • MTVA N/A
  • CING 2021
  • Fundamental
  • Price
  • MTVA $1.74
  • CING $4.62
  • Analyst Decision
  • MTVA Strong Buy
  • CING Strong Buy
  • Analyst Count
  • MTVA 1
  • CING 3
  • Target Price
  • MTVA $12.00
  • CING $16.00
  • AVG Volume (30 Days)
  • MTVA 57.9K
  • CING 222.0K
  • Earning Date
  • MTVA 03-27-2025
  • CING 11-07-2024
  • Dividend Yield
  • MTVA N/A
  • CING N/A
  • EPS Growth
  • MTVA N/A
  • CING N/A
  • EPS
  • MTVA N/A
  • CING N/A
  • Revenue
  • MTVA N/A
  • CING N/A
  • Revenue This Year
  • MTVA N/A
  • CING N/A
  • Revenue Next Year
  • MTVA N/A
  • CING N/A
  • P/E Ratio
  • MTVA N/A
  • CING N/A
  • Revenue Growth
  • MTVA N/A
  • CING N/A
  • 52 Week Low
  • MTVA $1.51
  • CING $1.80
  • 52 Week High
  • MTVA $6.75
  • CING $20.83
  • Technical
  • Relative Strength Index (RSI)
  • MTVA N/A
  • CING 47.61
  • Support Level
  • MTVA N/A
  • CING $4.35
  • Resistance Level
  • MTVA N/A
  • CING $5.09
  • Average True Range (ATR)
  • MTVA 0.00
  • CING 0.38
  • MACD
  • MTVA 0.00
  • CING -0.06
  • Stochastic Oscillator
  • MTVA 0.00
  • CING 32.93

About MTVA METAVIA INC

MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: